Biotherapeutics company PureTech Health plc (Nasdaq: PRTC) (LSE: PRTC) said on Monday that it has presented new results from the open-label extension of its Phase 2b ELEVATE IPF trial, showing that patients who switched from placebo or pirfenidone to deupirfenidone (LYT-100) achieved stabilization of lung function with favourable tolerability. Data were shared in a late-breaking presentation at the European Respiratory Society Congress in Amsterdam.

The 26-week randomised portion of ELEVATE IPF had already demonstrated a statistically significant and clinically meaningful reduction in forced vital capacity decline with deupirfenidone 825mg TID versus placebo and pirfenidone. In the extension, patients continuing on deupirfenidone maintained durable treatment effects over 52 weeks, with lung function decline comparable to that of healthy older adults. Switch patients also showed benefit, with placebo switchers recording a mean FVC gain of 20ml and pirfenidone switchers showing a decline of just 23.1ml.

Deupirfenidone was well tolerated, with a safety profile consistent with earlier trial phases. Common adverse events included dyspepsia, nausea, cough and upper respiratory infections.

Regulatory discussions are underway, with a Phase 3 trial design update expected in Q4 2025. PureTech said the results support the potential of deupirfenidone to become a new standard of care for idiopathic pulmonary fibrosis.